Literature DB >> 2693392

Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma.

I Könyves1.   

Abstract

This review presents the most important hormonal, cytotoxic and pharmacokinetic properties of estramustine phosphate. Furthermore the results of randomized Phase III trials are described in patients with hormone refractory prostatic cancer with and without previous irradiation. Several randomized studies are reported with Estracyt also in the primary treatment of this disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2693392     DOI： 10.1007/bf02559635

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  15 in total

1.  A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation.

Authors:  G P Murphy; R P Gibbons; D E Johnson; S A Loening; G R Prout; J D Schmidt; D S Bross; T M Chu; J F Gaeta; J Saroff; W W Scott
Journal:  J Urol       Date:  1977-08       Impact factor: 7.450

2.  French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.

Authors:  J Hauchecorne
Journal:  Prog Clin Biol Res       Date:  1987

3.  Hormone cytostatic agents.

Authors:  I Könyves
Journal:  Scand J Urol Nephrol Suppl       Date:  1980

4.  Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.

Authors:  R C Benson; G M Gill
Journal:  Am J Clin Oncol       Date:  1986-08       Impact factor: 2.339

5.  Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.

Authors:  P Björk; B Forsgren; J A Gustafsson; A Pousette; B Högberg
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

6.  Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.

Authors:  L Andersson; T Berlin; J Boman; L Collste; F Edsmyr; P L Esposti; H Gustafsson; P O Hedlund; L Hultgren; G Leander; O Nordle; H Norlén; P Tillegård
Journal:  Scand J Urol Nephrol Suppl       Date:  1980

7.  Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets.

Authors:  K D Tew; L C Erickson; G White; A L Wang; P S Schein; B Hartley-Asp
Journal:  Mol Pharmacol       Date:  1983-09       Impact factor: 4.436

8.  Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer.

Authors:  S A Loening; S Beckley; M F Brady; T M Chu; J B deKernion; C Dhabuwala; J F Gaeta; R P Gibbons; C F McKiel; D G McLeod; J E Pontes; G R Prout; P T Scardino; J U Schlegel; J D Schmidt; W W Scott; N H Slack; M S Soloway; G P Murphy
Journal:  J Urol       Date:  1983-05       Impact factor: 7.450

9.  Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.

Authors:  P O Hedlund; H Gustafson; S Sjögren
Journal:  Scand J Urol Nephrol Suppl       Date:  1980

10.  Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate.

Authors:  M S Soloway; J B deKernion; R P Gibbons; D E Johnson; S A Loening; J E Pontes; G R Prout; J D Schmidt; W W Scott; T M Chu; J F Gaeta; N H Slack; G P Murphy
Journal:  J Urol       Date:  1981-05       Impact factor: 7.450
View more
  1 in total

Review 1.  Second-line treatment of metastatic prostatic carcinoma.

Authors:  D W Newling
Journal:  Urol Res       Date:  1997
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.